Today's news alerts include: Inspire Announces Presentations at American Thoracic Society Annual Meeting
Data Presented from Phase 3 Cystic Fibrosis Trial with Denufosol Tetrasodium
DURHAM, N.C., May 15, 2009 -- Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today Inspire scientists and collaborators will present data at the American Thoracic Society (ATS) annual meeting May 15 - 20, 2009 in San Diego, CA.
The oral poster presentation, "Phase 3 Study of Denufosol Tetrasodium for the Treatment of Cystic Fibrosis" (R.B. Moss, R.D. Anbar, R.W. Wilmott, M. Barnes, A.E. Schaberg, T.A. Durham, F.J. Accurso), will take place during the poster discussion session, "New Data Regarding Cystic Fibrosis," on Sunday, May 17, 2009 from 8:15 AM - 10:45 AM.
Inspire will also have five presentations related to preclinical work conducted with novel Rho kinase inhibitors in respiratory-related applications.
These posters will be available on Inspire's website, www.inspirepharm.com, following the conference.
About Inspire
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical and scientific expertise. The most advanced compounds in Inspire's clinical pipeline are Prolacria(TM) for dry eye and denufosol tetrasodium for cystic fibrosis, which are both in Phase 3 development, and AzaSite(R) for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co-promotion of Elestat(R) for allergic conjunctivitis and royalties based on net sales of Restasis(R) for dry eye. For more information, visit www.inspirepharm.com.
About Xtremepicks.com
Xtremepicks.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
Xtremepicks.com is a leading stock website that provides free daily alerts on stocks that are moving up. xtremepicks.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@xtremepicks.com
Xtremepicks.com is an independent electronic publication that provides information on selected publicly traded companies. xtremepicks.com is not a registered investment advisor or broker-dealer. Xtremepicks.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.xtremepicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index